Gregory Hummer, MD

Founder & CEO, IdentifySensors Biologics | Former Level I Trauma Surgeon | Pioneering the first generation of digital cancer diagnostics with Check4®.

[Gregory Hummer, MD @GregoryHummerMD]

Hello, and thank you to everyone here working to improve cancer care.

I’m Gregory Hummer, MD, Founder & CEO of IdentifySensors Biologics. We’re pioneering the first generation of rapid, fully digital cancer mutation detection with Check4®, starting with EGFR and KRAS in NSCLC.

I’m excited to be here, share our progress, and learn from this community.

[Gregory Hummer, MD @GregoryHummerMD]

Preparedness is ultimately a race against time. A surveillance network is only as effective as the information reaching it. Connecting molecular testing in the field with global intelligence systems could help transform early warning into coordinated action before outbreaks escalate.

[Gregory Hummer, MD @GregoryHummerMD]

And then there’s the bigger question:

What happens when molecular data can be connected, analyzed and understood across locations in real time?

@HHSGov @WHO @FINDdx — worth exploring.

#GlobalHealth

[Gregory Hummer, MD @GregoryHummerMD]

What becomes possible when molecular testing moves closer to where an outbreak is unfolding — and the result itself is digital?

Connectivity can change what’s possible.

@Starlink, this intersection is worth exploring.

#PrecisionMedicine #DigitalDiagnostics

[Gregory Hummer, MD @GregoryHummerMD]

@WilliamShatner @ABC What a wonderful night ahead! Looking forward to seeing you and Brad on Kimmel tonight! 🖖

[Gregory Hummer, MD @GregoryHummerMD]

@dplanchard Could serial ctDNA monitoring eventually help identify patients who may benefit from treatment de-escalation? Certainly an interesting question for prospective trials.

[Gregory Hummer, MD @GregoryHummerMD]

@drshieldsmd @StephenVLiu @Joshua_Reuss @LUNGevity Who was crowned Prom King and Queen? 👑🫁

[Gregory Hummer, MD @GregoryHummerMD]

@elonmusk When disaster strikes, connectivity isn't a luxury. It's a lifeline.

Keeping emergency responders and medical teams connected can make all the difference.

A big step forward for Venezuela! 🇻🇪🛰️

[Gregory Hummer, MD @GregoryHummerMD]

@drgandara @ReckampK @FNIH_Org @SWOG @theNCI Congratulations on 10 years of Lung-MAP! The advances in biomarker-driven trials and translational research, particularly the work involving ctDNA, are exciting to see.

A wonderful example of collaboration moving precision oncology forward!

[Gregory Hummer, MD @GregoryHummerMD]

@aadel_chaudhuri @binaytara @semenko @JingZeng98195 ctDNA is opening a powerful window into cancer biology. The ability to detect and track molecular changes from blood could fundamentally change how we monitor disease and guide treatment.

Exciting work in precision oncology!

[Gregory Hummer, MD @GregoryHummerMD]

Study published in JCO Oncology Practice (June 2026):

https://t.co/tTLeJFZ3dK

[Gregory Hummer, MD @GregoryHummerMD]

27 days from biopsy to genomic profiling results.

A recent study in JCO Oncology Practice found that a median of 14 days passed before testing was even ordered in non-small cell lung cancer.

Precision oncology needs faster diagnostics AND more efficient clinical workflows.

#PrecisionOncology

[Gregory Hummer, MD @GregoryHummerMD]

@mayemusk @elonmusk @POTUS @JensenHuang @MichaelDell @satyanadella @LisaSu What an extraordinary group of innovators! 🚀 Their contributions have transformed what's possible across science and technology. Congratulations to Elon and all the honorees! 👏

[Gregory Hummer, MD @GregoryHummerMD]

@EricTopol @AACR @CD_AACR The downstream challenge is just as important. Once a pathogenic germline variant is identified, how consistently are we reaching at-risk family members and getting them into appropriate testing and surveillance?

[Gregory Hummer, MD @GregoryHummerMD]

@trevormundel Fascinating approach by Dr. Okeke and her team. The combination of molecular detection and portable sequencing could open important opportunities in resource-limited settings. Curious how quickly this workflow could deliver clinically actionable results.

[Gregory Hummer, MD @GregoryHummerMD]

@AMAEdHub @MLG_CME As biomarker testing becomes increasingly central to NSCLC care, turnaround time matters. How can we get actionable molecular information into physicians' hands sooner without compromising accuracy?

[Gregory Hummer, MD @GregoryHummerMD]

@elonmusk @Starlink The same principle applies to healthcare. Geography shouldn't determine access to advanced diagnostics. Connectivity has the potential to bring medical expertise and molecular testing to communities that need it most.

[Gregory Hummer, MD @GregoryHummerMD]

@DeryaTR_ @OpenAI Wait… is the billboard AI too? 😂 Congrats, Derya!

[Gregory Hummer, MD @GregoryHummerMD]

@agneeaztra @elonmusk Agreed. Availability matters, but affordability is what turns connectivity into real access.

[Gregory Hummer, MD @GregoryHummerMD]

@LUNGevity The gap between identifying an actionable biomarker and getting a patient onto matched therapy is such an important one. Where do you see the biggest barrier today — test ordering, turnaround time, or acting on the result?